title: Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.
abstract: Burkitt lymphoma/leukaemia is the most common (40%) form of non-Hodgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5-year event-free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1-2 year period. Currently, the prognosis for the same advanced stage has a 5-year EFS of 85-90% with <6 months of chemotherapy only. Radiation therapy has been eliminated for children and adolescents with Burkitt lymphoma/leukaemia except in emergencies, such as superior vena cava syndrome and acute neurological impairment or in patients with relapse/progression. Current risk factors in the prognosis of childhood and adolescent Burkitt lymphoma/leukaemia include: lactate dehydrogenase level ≥ 2× the upper normal limit at diagnosis, bone marrow and central nervous system involvement, poor response to cyclophosphamide, vincristine and prednisone reduction therapy and poor risk cytogenetics. New and novel therapeutic approaches include monoclonal antibody (anti-CD20) therapy, targeted cellular immune therapy and small molecule inhibitors. Future strategies should include improved staging and risk classification, reduction of cytotoxic chemotherapy, the investigation of targeted therapy, an increased understanding of the underlying biology of Burkitt lymphoma/leukaemia, strategies for prevention and approaches to reduce acute and chronic toxicities.
authors.affiliation: Department of Pathology, University of Utah, Salt Lake City, UT, USA. .
authors.forename: Rodney R
authors.initials: RR
authors.lastname: Miles
authors.forename: Staci
authors.initials: S
authors.lastname: Arnold
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D002648:Child; D002869:Chromosome Aberrations; D055028:Comparative Genomic Hybridization; D003937:Diagnosis, Differential; D020869:Gene Expression Profiling; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D018365:Neoplasm, Residual / Q000175:diagnosis; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000209:etiology